Barclays Cuts Agilon Health (NYSE:AGL) Price Target to $0.50

Agilon Health (NYSE:AGL) had its price objective decreased by Barclays from $1.00 to $0.50 in a research note published on Friday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Wells Fargo & Company dropped their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Royal Bank Of Canada upgraded shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $2.60.

Agilon Health Stock Down 1.1%

AGL stock opened at $0.59 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.02. Agilon Health has a one year low of $0.34 and a one year high of $6.08. The firm’s fifty day moving average is $0.71 and its 200 day moving average is $0.85. The firm has a market cap of $243.94 million, a PE ratio of -0.62 and a beta of 0.11.

Agilon Health (NYSE:AGL) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.46 billion. On average, research analysts forecast that Agilon Health will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Agilon Health by 3.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock valued at $927,000 after acquiring an additional 7,209 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its stake in shares of Agilon Health by 28.4% in the first quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after buying an additional 10,424 shares in the last quarter. Apollon Wealth Management LLC lifted its position in shares of Agilon Health by 17.4% during the fourth quarter. Apollon Wealth Management LLC now owns 82,348 shares of the company’s stock worth $57,000 after purchasing an additional 12,193 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Agilon Health in the 2nd quarter valued at approximately $31,000. Finally, Legal & General Group Plc grew its stake in Agilon Health by 4.1% during the 2nd quarter. Legal & General Group Plc now owns 346,031 shares of the company’s stock worth $796,000 after purchasing an additional 13,700 shares in the last quarter.

Key Headlines Impacting Agilon Health

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Wells Fargo upgraded AGL to “overweight” and raised its price target to $1.50 (from $1.00), implying meaningful upside from current levels — a bullish analyst signal that can support buying interest. Benzinga
• Neutral Sentiment: Q4 results were mixed: revenue beat estimates ($1.57B vs. ~$1.46B) but EPS missed materially (reported ($0.46) vs. consensus ($0.27)), leaving investors weighing top-line strength against profitability issues. Earnings Release/Transcript
• Neutral Sentiment: Management outlined a 2026 target (~$5.5B revenue and breakeven adjusted EBITDA) as part of a transformation plan — a constructive medium‑term goal but one that may be viewed skeptically given recent misses and execution risk. Seeking Alpha
• Negative Sentiment: Company guidance was lower than Street expectations (FY revenue midpoint and Q1 revenue below consensus), which increases downside risk as analysts rework models and investor confidence is tested. Seeking Alpha
• Negative Sentiment: Barclays cut its price target to $0.50 and moved to “underweight,” signaling additional analyst pessimism and potential further selling pressure. Benzinga
• Negative Sentiment: Multiple law firms have filed or are soliciting lead-plaintiff interest in securities class actions alleging fraud tied to Agilon, with several deadline reminders for March 2, 2026 — legal overhang and potential litigation costs are weighing on sentiment. GlobeNewswire

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.